Explore

Reuters Reuters
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.
Rapid Read Rapid Read
Promising Results from mRNA Vaccine Trial Against Pancreatic Cancer

Promising Results from mRNA Vaccine Trial Against Pancreatic Cancer

A clinical trial for a personalized mRNA vaccine against pancreatic cancer has shown promising results, with seven out of eight responders still alive six years after treatment. The trial, conducted by Memorial Sloan Kettering Cancer Center, involved 16 patients, half of whom developed a strong immune response to the vaccine. The vaccine is designed to target cancer cells remaining after surgery, preventing recurrence. The trial's success offers hope for a cancer type that is notoriously difficult to treat, with a low survival rate. The findings were presented at the American Association for Cancer Research meeting, highlighting the potential of mRNA technology in cancer treatment.
Rapid Read Rapid Read
DPP4 Deficiency in AML Mice Alters Leukemic Stem Cell Behavior and Distribution

DPP4 Deficiency in AML Mice Alters Leukemic Stem Cell Behavior and Distribution

Recent research has identified DPP4 as a significant factor in the behavior and distribution of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) models. The study found that DPP4 deficiency in AML mice leads to a redistribution of leukemic cells within the bone marrow, moving them from the metaphysis to the central marrow. This redistribution is associated with increased cell-cycle activity and a loss of LSC quiescence, resulting in higher rates of apoptosis. The findings suggest that DPP4 plays a crucial role in maintaining LSCs by supporting their survival and self-renewal capabilities. The study highlights the potential of targeting DPP4 as a therapeutic strategy in AML treatment.
Rapid Read Rapid Read
Pancreatic Cancer Vaccine Shows Promising Long-Term Results in Clinical Trial

Pancreatic Cancer Vaccine Shows Promising Long-Term Results in Clinical Trial

A personalized mRNA vaccine for pancreatic cancer has shown promising results in a phase 1 clinical trial, with extended follow-up data presented at the American Association for Cancer Research meeting. The trial involved 16 patients, half of whom developed a strong immune response to the vaccine. These 'responders' had a significantly lower recurrence rate and higher survival rate compared to non-responders. The vaccine is tailored to each patient's tumor antigens, aiming to prevent recurrence by targeting cancer cells remaining after surgery. The study, led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center, highlights the potential of personalized cancer vaccines, though further research is needed to confirm these findings.
Trendline Trendline
Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development

Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development

Verastem Oncology to Announce Q1 2026 Financial Results Amid Cancer Drug Development
Rapid Read Rapid Read
Heart's Mechanical Forces Found to Suppress Tumor Growth, Offering New Cancer Therapy Insights

Heart's Mechanical Forces Found to Suppress Tumor Growth, Offering New Cancer Therapy Insights

Researchers at the International Centre for Genetic Engineering and Biotechnology have discovered that the heart's constant beating may suppress tumor growth in cardiac tissues. The study highlights the role of mechanical forces in altering gene regulation in cancer cells, preventing their proliferation. Central to this process is the protein Nesprin-2, which transmits mechanical signals that reduce cancer cell activity. The findings suggest potential new cancer therapies based on mechanical stimulation.
Rapid Read Rapid Read
Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former Senator Ben Sasse Attributes Extended Life to Experimental Cancer Treatment

Former U.S. Senator Ben Sasse, diagnosed with stage 4 metastatic pancreatic cancer, credits an experimental drug for extending his life beyond initial expectations. Diagnosed in December and given a prognosis of three to four months, Sasse has seen a 76% reduction in tumor size due to a clinical trial involving the drug daraxonrasib. This treatment, developed by Revolution Medicines, has extended the life expectancy of patients from six to approximately thirteen months. Sasse discussed his journey and the impact of this treatment in an interview with Scott Pelley on '60 Minutes,' highlighting the role of faith and medical innovation in his ongoing battle with cancer.
Trendline Trendline
Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results

Vir Biotechnology Announces Upcoming Conference Call for Q1 2026 Financial Results
Rapid Read Rapid Read
Immune Checkpoint Inhibitors Show Promise in Treating Mediastinal B-Cell Lymphoma

Immune Checkpoint Inhibitors Show Promise in Treating Mediastinal B-Cell Lymphoma

Recent studies have shown that immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab are effective in treating relapsed or refractory primary mediastinal B-cell lymphoma (PMBCL). These therapies have demonstrated high overall response rates (ORR) in real-world settings, suggesting their potential use with curative intent. The PRIMICI trial, a multicenter retrospective study, included 74 patients with R/R PMBCL and reported an average ORR of 64% across both treatment groups. The study highlights the efficacy of ICIs, regardless of prior treatment history, and suggests that these therapies could offer long-term disease control.
Rapid Read Rapid Read
CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm Initiates Phase 2/3 Trial for Visugromab in Cancer Cachexia Treatment

CatalYm has commenced a Phase 2/3 trial for its anti-GDF-15 antibody, visugromab, targeting cancer-associated cachexia. The VINCIT trial aims to enroll 518 patients with cachexia linked to advanced cancers such as non-small cell lung cancer and colorectal cancer. Cachexia, characterized by severe weight loss and muscle wasting, affects up to 70% of cancer patients and contributes to 20-40% of cancer-related deaths. Visugromab works by neutralizing GDF-15, a cytokine involved in immune suppression and cachexia. The trial will assess the efficacy of visugromab in reversing cachexia, with primary endpoints including changes in body weight and appetite.
Rapid Read Rapid Read
Innovative Approaches in Cancer Research Target Dormancy to Transform Metastasis Therapy

Innovative Approaches in Cancer Research Target Dormancy to Transform Metastasis Therapy

Recent advancements in cancer research have highlighted the potential of targeting cancer dormancy to transform metastasis therapy. Supported by grants from the Samuel Waxman Institute for Aging and Cancer and the Department of Defence, researchers are focusing on the mechanisms of cancer cell dormancy and its role in metastasis. The study emphasizes the importance of understanding how dormant cancer cells can evade treatment and later cause metastasis. By targeting these dormant cells, researchers aim to prevent the reactivation of cancer and improve patient outcomes. This approach is seen as a promising avenue for developing new therapeutic strategies that could significantly impact cancer treatment.
Trendline Trendline
Daiichi Sankyo Delays Earnings Report, Shares Drop Amid Strategic Review

Daiichi Sankyo Delays Earnings Report, Shares Drop Amid Strategic Review

Daiichi Sankyo Delays Earnings Report, Shares Drop Amid Strategic Review